Asset Manager Exits Shares of Hims & Hers Health
Key Points
BLKBRD Asset Management exited 318,666 shares of Hims & Hers Health; estimated trade size $18.07 million, based on quarterly average pricing.
Quarter-end position value dropped by $18.07 million, reflecting the full liquidation and price movement.
Represents a 24.3% swing in 13F reportable AUM.
Post-trade stake: zero shares; $0 position value.
Hims & Hers Health previously accounted for 5.0% of the fund’s AUM before this liquidation.
- 10 stocks we like better than Hims & Hers Health ›
On February 17, 2026, BLKBRD Asset Management, LP, disclosed it sold out its entire stake in Hims & Hers Health (NYSE:HIMS), an estimated $18.07 million trade based on quarterly average pricing.
What happened
According to an SEC filing dated February 17, 2026, BLKBRD Asset Management, LP, sold all 318,666 shares of Hims & Hers Health during the fourth quarter. The estimated transaction value was $18.07 million, based on the average share price over the reporting period. The net position change also totaled $18.07 million, reflecting both the completed trade and any price movement through quarter-end.
What else to know
- The fund fully exited its Hims & Hers Health stake this quarter, which previously represented 5.0% of AUM as of the prior filing; post-trade, the position is zero.
- As of December 31, 2025, top holdings by value were:
- NASDAQ: NVDA: $4.66 million (6.3% of AUM).
- NASDAQ: GOOGL: $4.28 million (5.8% of AUM).
- As of February 16, 2026, Hims & Hers Health shares were priced at $16.30, down 72.46% over the past year, underperforming the S&P 500 by 84.25 percentage points.
Company overview
| Metric | Value |
|---|---|
| Price (as of market close February 13, 2026) | $16.30 |
| Market capitalization | $3.57 billion |
| Revenue (TTM) | $2.21 billion |
| Net income (TTM) | $133.79 million |
Company snapshot
- Offers a telehealth platform providing direct-to-consumer medical consultations, prescription medications, and a curated portfolio of wellness, skincare, sexual health, and hair care products.
- Generates revenue through recurring prescription services, over-the-counter product sales, and wholesale partnerships, leveraging a digital-first, subscription-based model.
- Targets health-conscious consumers seeking accessible, discreet, and ongoing care, primarily in the United States.
Hims & Hers Health operates a multi-specialty telehealth platform at scale, integrating digital healthcare delivery with a broad range of consumer wellness products. The company’s strategy centers on recurring revenue from subscriptions and direct sales, supported by a robust digital infrastructure. Its competitive edge lies in combining medical consultation, prescription fulfillment, and branded wellness products within a seamless, consumer-centric online experience.
What this transaction means for investors
Hims & Hers stock has been in freefall since last June when it was trading near an all-time high at $64 per share. By early March of this year, the stock had plummeted to around $15 per share.
The catalyst for the drop was Novo Nordisk (NYSE:NVO) terminating its partnership with Hims & Hers to sell its weight-loss drugs. Novo Nordisk also sued Hims & Hers, claiming they were selling copycat weight loss drugs. Hims & Hers Health was one of the most shorted midcap stocks by institutional investors in January, according to the Hazeltree Crowdedness Report.
But Hims & Hers stock was soaring on Tuesday, March 10, after the company announced a new partnership with Novo Nordisk to offer its weight-loss drugs Ozempic and Wegovy on its platform. As part of the deal, Novo Nordisk dropped its lawsuit against Hims & Hers.
The stock was up some 6% on March 10 on the news. Hims & Hers stock is still trading at a high multiple, but this big news may provide an opportunity for investors to reassess Hims & Hers prospects.
Should you buy stock in Hims & Hers Health right now?
Before you buy stock in Hims & Hers Health, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Hims & Hers Health wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $530,233!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,119,682!*
Now, it’s worth noting Stock Advisor’s total average return is 955% — a market-crushing outperformance compared to 191% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of March 10, 2026.
Dave Kovaleski has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Advanced Micro Devices, Alphabet, Hims & Hers Health, Nvidia, and Oracle. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.
Recommended Articles
